Inhaled Delivery for Systemic Drug Therapies Gaining Momentum
New Survey by Greystone Finds Pulmonary Formulations in Various Stages of Development with Significant Potential
(Amherst, NH) – The search for improved routes of administration and the desire for noninvasive delivery methods for self-medication of chronic conditions have led to increased interest in alternative drug delivery systems. At the development level, this interest has led to recent improvements in drug formulation and inhalation device design that are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods.
These developments are attracting new players and new investment, accelerating the pace and number of new pulmonary delivery candidates entering the drug development pipeline. “While inhaled insulin - with its demand profile, favorable market outlook and quality-of-life implications - is the focus of media attention, more than a dozen other important disease therapies and treatment options have been quietly winding their way through the development and clinical trial process,” explains George Perros, Greystone Associates Managing Director.
These new combination products include inhaled drugs for the treatment of such diverse conditions as endometriosis, several forms of cancer, hemophilia, MS, neurological disorders and pain management. “Several of these emerging drug products will have a significant impact in the therapeutic markets they target, effectively changing the way important illnesses and conditions are treated,“ adds Perros.
These findings are contained in a new and comprehensive report: Emerging Inhalation Therapeutics. Growth of inhaled drugs will be driven by a number of factors, including improved patient compliance and patient quality-of-care, and the trend toward drug therapy self-administration.
More information is available at www.greystoneassociates.org
.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
marksmith@greystoneassociates.org
www.greystoneassociates.org
